Meta-Analysis: The Impact of Nutritional Status on the Immune Response to Hepatitis B Virus Vaccine in Chronic Kidney Disease

Fabrizi, Fabrizio; Dixit, Vivek; Martin, Paul; Jadoul, Michel; Messa, Piergiorgio

doi:10.1007/s10620-011-1987-1

Cited by 30 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4) and chronic kidney disease (ICD-9-CM code 585). These comorbidities were adjusted for their possible role in liver microenvironment (24)(25)(26). Geographic regions, urbanization level of residence and socioeconomic status information were adjusted for possible uneven medical resources to prevent information bias.…”

Section: Measurements Of End-points and Covariatesmentioning

confidence: 99%

Effect of liver cirrhosis on metastasis in colorectal cancer patients: a nationwide population-based cohort study

Chiou

Chang

Tseng

et al. 2014

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: The aim of this study is to evaluate the liver metastasis risk among colorectal cancer patients with liver cirrhosis. Methods: This was a nationwide population-based cohort study of 2973 newly diagnosed colorectal cancer patients with liver cirrhosis and 11 892 age-sex matched controls enrolled in Taiwan between 2000 and 2010. The cumulative risk by Kaplan-Meier method, hazard ratio by the multivariate Cox proportional model and the incidence density were evaluated. Results: The median time interval from the colorectal cancer diagnosis to the liver metastasis event was 7.42 months for liver cirrhosis group and 7.67 months for non-liver cirrhosis group. The incidence density of liver metastasis was higher in the liver cirrhosis group (61.92/1000 person-years) than in the non-liver cirrhosis group (47.48/1000 person-years), with a significantly adjusted hazard ratio of 1.15 (95% CI = 1.04-1.28, P = 0.007). The 10-year cumulative risk of liver metastasis for the liver cirrhosis and the non-liver cirrhosis group was 27.1 and 23.6%, respectively (P = 0.006). For early cancer stage with locoregional disease patients receiving surgery alone without adjuvant anti-cancer treatments, patients with liver cirrhosis (10-year cumulative risk 23.9 vs. 15.7%, P < 0.001) or cirrhotic symptoms (10-year cumulative risk 25.6 vs. 16.6%, P = 0.009) both still had higher liver metastasis risk compared with their counterparts. For etiologies of liver cirrhosis, the 10-year cumulative risk for hepatitis B virus and hepatitis C virus, hepatitis B virus, hepatitis C virus, other causes and nonliver cirrhosis were 29.5, 28.9, 27.5, 26.7 and 23.4%, respectively, (P = 0.03). Conclusions: Our study found that liver metastasis risk was underestimated and even higher in colorectal cancer patients with liver cirrhosis.

show abstract

Section: Measurements Of End-points and Covariatesmentioning

confidence: 99%

Effect of liver cirrhosis on metastasis in colorectal cancer patients: a nationwide population-based cohort study

Chiou

Chang

Tseng

et al. 2014

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Because the body weight represents the nutritional status of a patient, it may influence the immune response to vaccination, although there are many other factors associated with an immunization response. A meta‐analysis has described the relationship of a poor nutritional status and an impaired serologic response with inactivated hepatitis B virus vaccine in patients with chronic kidney diseases . There are also intriguing reports on how the potential of nutrition‐dependent adipocyte‐derived hormones can affect the induction and maintenance of a proinflammatory T helper 1 immune response .…”

Section: Discussionmentioning

confidence: 99%

“…A meta-analysis has described the relationship of a poor nutritional status and an impaired serologic response with inactivated hepatitis B virus vaccine in patients with chronic kidney diseases. 19 There are also intriguing reports on how the potential of nutrition-dependent adipocyte-derived hormones can affect the induction and maintenance of a proinflammatory T helper 1 immune response. [20][21][22] According to the multivariate analysis, we found that a seronegative status after mumps vaccination was independently associated with underlying diseases other than biliary atresia.…”

Section: Discussionmentioning

confidence: 99%

Serostatus following live attenuated vaccination administered before pediatric liver transplantation

et al. 2015

View full text Add to dashboard Cite

After liver transplantation (LT), live attenuated vaccines (LAVs) are generally contraindicated. LAVs are recommended before LT for patients 6 months of age. However, the evidence supporting this practice is limited. Patients were enrolled before and after LT. Clinical data for patients were obtained from medical records. Serum antibody titers were evaluated at the time of enrollment and prospectively. Serum antibody titers were measured with a hemagglutination inhibition test for measles and rubella and with an enzyme-linked immunosorbent assay for varicella and mumps. Univariate and multivariate analyses were performed to investigate the factors that affect the serostatus. Serological analyses of 49 patients immunized before LT (median age, 45 months; male, 35%) were performed. Underlying diseases were biliary atresia (n 5 27; 55%), metabolic diseases (n 5 13; 27%), fulminant hepatic failure (n 5 5; 10%), and others (n 5 4; 8%). The seropositivity rate after each vaccine was 46.9% (measles), 89.4% (rubella), 67.5% (varicella), and 48.8% (mumps). Factors independently associated with seronegativity were a vaccination age < 12 months for measles (P 5.002), a lower body weight for varicella (P 5 0.01), and underlying diseases other than biliary atresia for mumps (P 5.004). No serious adverse event was observed during the study period. The immunogenicity of LAVs before LT was high for rubella but low for the others. Before LT, further vaccination strategies are needed for patients. In addition, serological follow-up may be indicated for patients with factors associated with seronegativity. Liver Transpl 21:774-783, 2015. V C 2015 AASLD.Received December 11, 2014; accepted February 26, 2015. Organ transplant candidates and recipients are at higher risk for infectious complications. In this particular population, vaccine-preventable diseases such as measles 1 and varicella 2 can actually be lifethreatening. For these individuals, inactivated vaccines are considered safe and are usually Additional Supporting Information may be found in the online version of this article.

show abstract

“…A detailed description of all these approaches is beyond the scope of this review. The rationale, development and utilization of preS-containing hepatitis B vaccines are presented in another contribution Male gender [12,54] Older age [20,21] Obesity (BMI ≥ 30) [12,55] Malnutrition [56] Lifestyle…”

Section: Strategies To Improve Protection Elicited By Hepatitis B Vacmentioning

confidence: 99%

Old and new adjuvants for hepatitis B vaccines

Leroux‐Roels

2014

Med Microbiol Immunol

View full text Add to dashboard Cite

The safety and immunogenicity profiles of currently available recombinant hepatitis B vaccines are excellent. However, it remains a real challenge to induce protective immunity in the target groups that respond poorly or not at all to conventional vaccines. Ideally, a hepatitis B vaccine can be developed that conveys lifelong protection against infection rapidly after the injection of a single dose. Although this goal is far from being reached, important improvements have been made. Novel vaccine adjuvants have been developed that enhance the immunogenicity of recombinant hepatitis B vaccines while maintaining a good safety profile. The different adjuvants and adjuvant systems that are discussed herein have all been thoroughly evaluated in clinical trials and some have reached or are close to reach the market.

show abstract

Meta-Analysis: The Impact of Nutritional Status on the Immune Response to Hepatitis B Virus Vaccine in Chronic Kidney Disease

Cited by 30 publications

References 31 publications

Effect of liver cirrhosis on metastasis in colorectal cancer patients: a nationwide population-based cohort study

Effect of liver cirrhosis on metastasis in colorectal cancer patients: a nationwide population-based cohort study

Serostatus following live attenuated vaccination administered before pediatric liver transplantation

Old and new adjuvants for hepatitis B vaccines

Contact Info

Product

Resources

About